false

Vann Parker

Vann Parker is the Head of Regulatory Consultancy (North America) for Precision for Medicine. He received his PhD in Molecular Biology from The California Institute of Technology and spent the past 30 years supporting biopharmaceutical and drug development. He currently focuses on strategies for clinical development and interactions with FDA and other regulatory agencies. In addition to support of pre-IND activities, Vann has supported sponsors throughout the drug development process including applications for Fast Track, Breakthrough Therapy and Orphan Designations, formal meetings with FDA and full NDA/BLA submissions.

• Read: Considerations for Your Pre-IND Meeting With the FDA

  Clinical Trials - Regulatory

  Considerations for Your Pre-IND Meeting With the FDA

  May 25, ‘24 | 3 min read

  • 

    Vann Parker

  Discover
• Read: FDA Draft Guidance Encourages Broader Inclusion Criteria in Oncology Trials

  Regulatory - Oncology

  FDA Draft Guidance Encourages Broader Inclusion Criteria in Oncology Trials

  May 22, ‘24 | 4 min read

  • 

    Vann Parker

  Discover
• Read: FDA Guidance on Pediatric Drug Development

  Clinical Trials - Regulatory - Rare Diseases

  FDA Guidance on Pediatric Drug Development

  Jul 25, ‘23 | 5 min read

  • 

    Vann Parker

  Discover
• Read: FDA Accelerated Approval for Oncology Therapeutics: Clinical Trial Considerations

  Clinical Trials - Regulatory - Oncology

  FDA Accelerated Approval for Oncology Therapeutics: Clinical Trial Considerations

  Jun 19, ‘23 | 3 min read

  • 

    Vann Parker

  Discover
• Read: FDA Procedural Guidance: Expansion Cohorts in FIH Oncology Clinical Trials

  Clinical Trials - Rare Diseases

  FDA Procedural Guidance: Expansion Cohorts in FIH Oncology Clinical Trials

  Jan 26, ‘23 | 4 min read

  • 

    Vann Parker

  Discover

Loading...

You've reach the end Back to top